NAD+ Peptide

Key findings in NAD+ longevity research:

• NAD+ levels decline ~50% between ages 40-60 in humans (Massudi et al., 2012)
• NAD+ supplementation restored muscle function in aged mice to young-adult levels (Zhang et al., Science 2016)
• SIRT1 activation via NAD+ repletion improved insulin sensitivity, reduced inflammation, and enhanced mitochondrial biogenesis
• Direct NAD+ IV administration (clinical pilot, Japan) improved fatigue scores and NAD+/NADH ratio in elderly subjects

PARP-1 is the primary NAD+-consuming DNA repair enzyme. Each single-strand break repair event consumes approximately 100-150 NAD+ molecules. With aging, accumulated DNA damage dramatically increases PARP activity, creating a NAD+ depletion spiral: more damage → more PARP activity → less NAD+ → impaired repair → more damage. Research shows NAD+ repletion breaks this cycle by restoring the substrate pool for efficient DNA repair.

NAD+ oscillates with circadian rhythm, peaking during active/waking periods. SIRT1 and NAMPT (the rate-limiting NAD+ synthesis enzyme) are clock-controlled genes. Declining NAD+ with age disrupts circadian gene oscillation, contributing to the sleep fragmentation, altered cortisol patterns, and metabolic dysregulation seen in aging. NAD+ supplementation research demonstrates partial restoration of circadian amplitude.

NAD+ depletion is implicated in multiple neurodegenerative conditions. In Alzheimer research, reduced NAD+ correlates with impaired mitochondrial function, increased tau phosphorylation, and amyloid-beta accumulation. NAD+ supplementation in AD mouse models (3xTg-AD) reduced neuroinflammation, improved synaptic plasticity, and enhanced cognitive performance.

In Parkinson disease models, NAD+ repletion protected dopaminergic neurons by maintaining mitochondrial Complex I function (the primary site of PD pathology) and activating SIRT3-mediated mitochondrial quality control via mitophagy.

NAD+ plays a critical role in immune cell metabolism. CD38, the primary NAD+-consuming enzyme, is also the most abundant ectoenzyme on immune cells. During inflammation, CD38 expression increases dramatically on macrophages and T-cells, creating local NAD+ depletion that paradoxically impairs the immune response. NAD+ supplementation research shows: restored macrophage phagocytic function, enhanced T-cell proliferative capacity, improved NK cell cytotoxicity, and reduced inflammatory cytokine overproduction ("cytokine storm" mitigation).

Some of the most influential NAD+ research has examined whether restoring NAD+ levels in aged organisms can reverse hallmarks of aging. A landmark 2013 study by Gomes et al., published in Cell, demonstrated that raising NAD+ levels in 22-month-old mice (equivalent to approximately 60 human years) reversed multiple markers of aging within one week of treatment.

Key findings from this and related investigations include:

• Mitochondrial function: After NAD+ repletion, skeletal muscle from aged mice showed mitochondrial parameters indistinguishable from 6-month-old mice, as measured by oxygen consumption rate and citrate synthase activity.
• SIRT1 activation: NAD+ repletion restored SIRT1 deacetylase activity, leading to reduced acetylation of PGC-1α and enhanced mitochondrial biogenesis gene expression.
• Pseudohypoxic state reversal: Aged tissues exhibited a "pseudohypoxic" transcriptional state driven by HIF-1α stabilization. NAD+ repletion normalized HIF-1α signaling within 7 days.
• Exercise capacity: Aged mice treated with NAD+ precursors showed 56–80% improvements in treadmill endurance compared to untreated age-matched controls.

These results provided foundational evidence that NAD+ decline is not merely a biomarker of aging but a causal contributor to mitochondrial dysfunction. The study has been cited over 2,400 times and catalyzed the current wave of NAD+-focused aging research.

The relationship between NAD+ availability and genomic stability has been a major focus of research, particularly in the context of PARP-dependent DNA repair. A 2014 study by Fang et al. investigated NAD+ supplementation in Cockayne syndrome (CS) mouse models, which exhibit accelerated aging due to defective nucleotide excision repair.

Study details and results:

• Model: CSB (Cockayne syndrome group B) mutant mice, characterized by neurodegeneration, hearing loss, and premature death.
• Intervention: NAD+ precursor supplementation for 2–3 months beginning at weaning.
• DNA damage: Treated CSB mice showed 40–50% reduction in γH2AX foci (a marker of DNA double-strand breaks) across multiple tissues including cerebellum and cochlea.
• Neurological outcomes: Treated animals demonstrated improved cerebellar Purkinje cell survival and partial rescue of hearing function compared to untreated CSB controls.
• Mechanistic pathway: NAD+ repletion reduced PARP hyperactivation, preventing NAD+ depletion-driven mitophagy defects and restoring mitochondrial membrane potential.

This research established that NAD+ depletion and PARP hyperactivation form a vicious cycle in DNA repair-deficient conditions: DNA damage activates PARP, which consumes NAD+, reducing sirtuin activity and mitochondrial quality control, leading to further cellular stress. These findings have been extended to models of Xeroderma pigmentosum and Ataxia telangiectasia, suggesting a conserved mechanism across multiple DNA repair disorders.

NAD+ levels oscillate in a circadian manner, and research has revealed a bidirectional relationship between NAD+ metabolism and the molecular clock. A seminal 2009 study by Ramsey et al. in Science demonstrated that the circadian transcription factor CLOCK:BMAL1 directly regulates expression of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway.

Key findings from circadian-NAD+ research include:

• Oscillation amplitude: Intracellular NAD+ levels fluctuate by approximately 25–30% over the 24-hour cycle, peaking during the active phase in murine liver.
• SIRT1 feedback loop: The NAD+ oscillation drives rhythmic SIRT1 activity, which in turn deacetylates BMAL1 and PER2, modulating clock gene transcription. This creates a metabolic feedback loop linking nutrient sensing to circadian regulation.
• Aging disruption: In aged mice, the amplitude of NAD+ oscillation is significantly dampened, correlating with flattened circadian gene expression and disrupted sleep-wake cycles.
• Restoration: NAD+ precursor supplementation in aged mice partially restored circadian oscillation amplitude and improved activity rhythms over a 6-week treatment period.

These findings suggest that NAD+ decline may contribute to the well-documented deterioration of circadian function with age, and that NAD+ repletion strategies may have relevance for chronobiology research beyond traditional metabolic endpoints.

NAD+ depletion has been implicated in the pathogenesis of neurodegenerative diseases, with Alzheimer's disease (AD) models receiving particular attention. A comprehensive 2019 study by Hou et al. in Proceedings of the National Academy of Sciences examined NAD+ supplementation in the 3×TgAD triple-transgenic mouse model of Alzheimer's disease, which develops amyloid plaques, neurofibrillary tangles, and cognitive deficits.

Study design and outcomes:

• Duration: 3 months of NAD+ precursor administration beginning at 5 months of age (pre-symptomatic stage).
• Amyloid pathology: Treated mice showed a ~50% reduction in hippocampal amyloid-β42 levels and decreased amyloid plaque burden compared to vehicle-treated controls.
• Tau phosphorylation: Hyperphosphorylated tau (AT8 immunoreactivity) was reduced by approximately 35% in the hippocampus of treated animals.
• Cognitive function: Morris water maze testing revealed significantly improved spatial learning and memory in treated mice, with latency to platform reduced to levels comparable to wild-type animals.
• Neuroinflammation: SIRT3-dependent mechanisms reduced microglial activation and lowered levels of pro-inflammatory cytokines IL-1β and TNF-α in brain tissue.
• DNA damage: Treated mice displayed reduced neuronal DNA damage as measured by comet assay and 8-OHdG staining.

The study concluded that NAD+ supplementation attenuated AD-related pathology through multiple convergent mechanisms including enhanced mitophagy, reduced neuroinflammation, and improved DNA repair capacity. These findings have stimulated interest in NAD+ metabolism as a potential target for neurodegenerative disease research.

The interplay between NAD+ metabolism and immune function has emerged as a rapidly growing area of investigation, particularly concerning the role of CD38 in age-related immune dysfunction ("inflammaging"). Research by Covarrubias et al. (2020) in Nature Metabolism provided critical insights into how tissue-resident macrophages drive NAD+ decline through CD38 upregulation.

Key findings from immune-NAD+ research:

• CD38 source identification: Tissue-resident M1-polarized macrophages and endothelial cells, rather than parenchymal cells, were identified as the primary sources of CD38 upregulation in aged tissues.
• Inflammatory signaling: Senescence-associated secretory phenotype (SASP) factors from senescent cells drove CD38 expression in neighboring macrophages, creating a paracrine NAD+ degradation loop.
• NAD+ depletion magnitude: In visceral adipose tissue from aged mice, CD38 activity accounted for an estimated 2–3 fold increase in NAD+ degradation rate compared to young tissue.
• Functional consequences: NAD+ depletion shifted macrophage polarization toward a pro-inflammatory M1 phenotype, reducing anti-inflammatory IL-10 production and increasing TNF-α and IL-6 secretion.
• Reversal: Both CD38 inhibition and NAD+ repletion in aged murine bone marrow-derived macrophages restored balanced M1/M2 polarization and improved phagocytic capacity.

These findings revealed a previously unrecognized link between cellular senescence, immune cell NAD+ consumption, and tissue-wide NAD+ depletion. The research has implications for understanding age-related immune dysfunction and has been cited as evidence that NAD+ metabolism sits at the intersection of inflammaging and metabolic decline.

A landmark study by Gomes et al. (2013) at Harvard Medical School investigated whether age-related decline in NAD+ levels contributes to mitochondrial dysfunction independently of canonical mitochondrial biogenesis pathways. Using 22-month-old C57BL/6 mice, the researchers administered the NAD+ precursor nicotinamide mononucleotide (NMN) at 500 mg/kg/day intraperitoneally for 7 days and measured mitochondrial homeostasis markers in skeletal muscle.

Key findings:

• NAD+ levels in aged muscle tissue were restored to levels comparable to 6-month-old young controls after 1 week of NMN administration
• Markers of mitochondrial function — including ATP content, citrate synthase activity, and oxidative phosphorylation complex subunit expression — were normalized to youthful levels
• The mechanism was identified as a SIRT1-HIF-1α-TFAM axis: declining NAD+ leads to reduced SIRT1 activity, allowing HIF-1α stabilization under normoxic conditions, which disrupts nuclear-mitochondrial communication
• Mitochondrial DNA-encoded OXPHOS subunits were selectively reduced in aged tissue, a defect reversed by NAD+ repletion
• The effect was independent of PGC-1α, the canonical mitochondrial biogenesis regulator, identifying a parallel pathway for mitochondrial maintenance

This study established the concept of "pseudohypoxia" — a state in which aged cells behave as though oxygen-deprived due to NAD+/SIRT1 collapse, even when oxygen is abundant. The work provided foundational rationale for NAD+ precursor research in sarcopenia and metabolic aging.

Subsequent investigations by Mills et al. (2016) extended these findings, demonstrating that 12 months of oral NMN administration in mice mitigated age-associated physiological decline across multiple tissues including muscle, liver, and adipose, without observable toxicity. These preclinical results have informed ongoing clinical investigation of NAD+ precursors in age-related metabolic dysfunction.

Cardiovascular tissues exhibit some of the highest NAD+ turnover rates in the body, and accumulating evidence implicates NAD+ decline in age-related cardiac dysfunction. de Picciotto et al. (2016) at the University of Colorado Boulder investigated whether NAD+ repletion could rescue endothelial dysfunction in aged mice.

Study design: Old (26-28 months) and young (4-6 months) C57BL/6 mice received NMN (300 mg/kg/day) in drinking water for 8 weeks. Vascular function was assessed via ex vivo aortic ring tension studies and arterial stiffness measurements.

Key findings:

• NMN supplementation restored endothelium-dependent dilation in aged aortas to levels not different from young controls (peak dilation: ~88% vs ~57% in untreated old mice)
• Aortic pulse wave velocity, a marker of arterial stiffness, was reduced by approximately 25% in NMN-treated aged mice
• Vascular oxidative stress (measured by superoxide production) was normalized to young levels
• NAD+ tissue levels in aortic tissue increased ~1.6-fold with treatment

In parallel research, Diguet et al. (2018) demonstrated that NAD+ precursor supplementation prevented cardiac dysfunction in murine models of dilated cardiomyopathy. Mice with a cardiomyocyte-specific NAD+ depletion phenotype developed heart failure that was rescued by nicotinamide riboside administration, with restoration of mitochondrial function and reduction of cardiac hypertrophy markers.

These findings position NAD+ metabolism as a target of intense investigation for vascular aging, heart failure with preserved ejection fraction (HFpEF), and ischemia-reperfusion injury — though all clinical translation remains in early-phase trials.

While direct intravenous NAD+ administration remains primarily a research procedure, the bulk of human clinical data comes from oral NAD+ precursor studies (NR, NMN). These trials provide important context for understanding NAD+ pharmacology in humans.

Trammell et al. (2016) conducted the first human pharmacokinetic study of nicotinamide riboside. Twelve healthy adults received single oral doses of 100, 300, or 1000 mg NR. Results demonstrated:

• Whole-blood NAD+ increased in a dose-dependent manner, with peak elevation of ~2.7-fold above baseline at the 1000 mg dose
• Elevated NAD+ levels persisted for up to 24 hours post-dose
• No serious adverse events; mild flushing reported infrequently

Martens et al. (2018) performed a 6-week crossover trial of NR (500 mg twice daily) in 30 middle-aged and older adults. Findings included:

• Whole-blood NAD+ increased 60% versus placebo
• Systolic blood pressure was reduced by ~8 mmHg in participants with stage 1 hypertension
• Aortic stiffness showed a non-significant downward trend
• Treatment was well-tolerated with no clinically meaningful adverse effects

Yoshino et al. (2021) reported the first clinical trial of NMN in 25 postmenopausal women with prediabetes. After 10 weeks of 250 mg/day NMN:

• Muscle insulin sensitivity (M-value) improved by ~25% compared to placebo
• Muscle expression of platelet-derived growth factor receptor was altered, suggesting remodeling pathways
• NMN was safe and well-tolerated throughout the trial

These data establish that oral NAD+ precursors reliably elevate systemic NAD+ in humans with favorable safety profiles, providing the empirical foundation for ongoing Phase 2 and Phase 3 trials in metabolic, cardiovascular, and neurodegenerative indications.